Literature DB >> 9674736

High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery.

M Trossaërt1, A Gaillard, P L Commin, J Amiral, A M Vissac, E Fressinaud.   

Abstract

Fifty-one patients undergoing cardiopulmonary bypass (CPB) were studied on day 0 and day 8 for heparin-induced thrombocytopenia (HIT). The platelet aggregation test (PAT) and tests for anti-heparin-platelet factor 4 (anti-H.PF4), anti-IL8 and anti-neutrophil activating peptide 2 (anti-NAP2) antibodies (Ab) were performed by ELISA. On day 8, 27% of patients were positive for anti-H.PF4Ab. None of these results were found to influence thrombotic complications or platelet counts after CPB. Our results suggest that IgG to H.PF4 may be considered a risk factor, but that additional factors must be required for HIT to develop. We conclude that assays based on platelet activation would be more appropriate for the diagnosis of HIT after CPB.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9674736     DOI: 10.1046/j.1365-2141.1998.00750.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  Pharmacogenetics to prevent heparin-induced thrombocytopenia: what do we know?

Authors:  Jason H Karnes
Journal:  Pharmacogenomics       Date:  2018-11-06       Impact factor: 2.533

2.  Can lean body mass be used to reduce the dose of heparin and protamine for obese patients undergoing cardiopulmonary bypass?

Authors:  Mya S Baker; Julian R Skoyles; Frca Matt Shajar; Henry Skinner; David Richens; Ian M Mitchell
Journal:  J Extra Corpor Technol       Date:  2005-06

3.  Improved prediction of HIT in the SICU using an improved model of the Warkentin 4-T system: 3-T.

Authors:  Matthew B Bloom; Jeffrey Johnson; Oksana Volod; Ernest Y Lee; Terris White; Daniel R Margulies
Journal:  Am J Surg       Date:  2019-07-29       Impact factor: 2.565

4.  Natural language processor as a tool to assess heparin induced thrombocytopenia awareness.

Authors:  Alfonso J Tafur; Robert D McBane; Waldemar E Wysokinski; Melissa S Gregg; Paul R Daniels; David N Mohr
Journal:  J Thromb Thrombolysis       Date:  2012-01       Impact factor: 2.300

Review 5.  Diagnostic accuracy of IgG-specific versus polyspecific enzyme-linked immunoassays in heparin-induced thrombocytopenia: a systematic review and meta-analysis.

Authors:  H D Husseinzadeh; P A Gimotty; A M Pishko; M Buckley; T E Warkentin; A Cuker
Journal:  J Thromb Haemost       Date:  2017-05-11       Impact factor: 5.824

6.  Use of bivalirudin as an anticoagulant during cardiopulmonary bypass.

Authors:  James J Veale; Harry M McCarthy; George Palmer; Cornelius M Dyke
Journal:  J Extra Corpor Technol       Date:  2005-09

7.  High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.

Authors:  Grace M Lee; Ian J Welsby; Barbara Phillips-Bute; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

Review 8.  Immune pathogenesis of heparin-induced thrombocytopenia.

Authors:  Sanjay Khandelwal; Gowthami M Arepally
Journal:  Thromb Haemost       Date:  2016-07-28       Impact factor: 5.249

Review 9.  Diagnosis and management of heparin-induced thrombocytopenia.

Authors:  Grace M Lee; Gowthami M Arepally
Journal:  Hematol Oncol Clin North Am       Date:  2013-04-13       Impact factor: 3.722

10.  Intraoperative anticoagulation management during cardiac transplantation for a patient with heparin-induced thrombocytopenia and a left ventricular assist device.

Authors:  Yasmin Wadia; John R Cooper; Arthur W Bracey; Katheleen Pinto; O H Frazier
Journal:  Tex Heart Inst J       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.